EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oneness Biotech Co's enterprise value is NT$24,147.8 Mil.
Oneness Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-685.7 Mil. Therefore, Oneness Biotech Co's EV-to-EBITDA for today is -35.22.
The historical rank and industry rank for Oneness Biotech Co's EV-to-EBITDA or its related term are showing as below:
ROCO:4743'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15021.3 Med: -39.51 Max: 946.6
Current: -35.22
During the past 13 years, the highest EV-to-EBITDA of Oneness Biotech Co was 946.60. The lowest was -15021.30. And the median was -39.51.
ROCO:4743's EV-to-EBITDA is ranked worse than 100% of 505
companies
in the Biotechnology industry
Industry Median: 7.78
vs ROCO:4743: -35.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Oneness Biotech Co EV-to-EBITDA Historical Data
The historical data trend for Oneness Biotech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oneness Biotech Co's EV-to-EBITDA
For the Biotechnology subindustry, Oneness Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's EV-to-EBITDA falls into.
Oneness Biotech Co's current Enterprise Value is NT$24,147.8 Mil.
Oneness Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-685.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co (ROCO:4743) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oneness Biotech Co's PE Ratio (TTM) for today is calculated as:
Oneness Biotech Co's share price for today is NT$63.30.
Oneness Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.413.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Oneness Biotech Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The company's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, OB318, and others. Along with its subsidiaries, the company operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:4743 has been successfully added to your 